Iconic Therapeutics

Iconic Therapeutics

A pharmaceutical company developing tissue factor therapies for the treatment of cancer and diseases.

Iconic Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco focused on retinal disease and cancer. The company's expertise lies in tissue factor (TF) biology. TF is a protein that plays a key role in inflammation and pathological angiogenesis (the formation of abnormal new blood vessels). Iconic Therapeutics is building a new class of TF therapeutics (mAB) in which the protein is overexposed, pursuing promising opportunities such as treating wet age-related macular degeneration (AMD) and certain solid tumors.

In May 2018, in the area of opthalmology, Iconic's first-generation fusion protein (ICON-1) has demonstrated target engagement, biologic activity, and the ability to impact clinical endpoints in a controlled Phase 2 trial. It is a fusion protein that binds to TF overexposed in the retina and the choroidal neovascularization (CNV) of AMD patients. The antibody is expected to enter formal IND-enabling studies in 2019.

In the area of cancer, TF overexpression on tumors, tumor vasculature, and the tumor microenvironment is a key attribute of multiple solid tumors. Iconic's propriety antibody drug conjugate (ADC), mAb targets TF without interfering with blood clotting. This ADC is expected to enter formal IND-enabling studies in 2019 as well.

Timeline

April 2014

Iconic Therapeutics raises a $20,000,000 series B round from MPM Capital and H.I.G. BioVentures.

January 17, 2009

Iconic Therapeutics raises a $2,500,000 series C round from Advanced Technology Development Center.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Brandon Smith

COO

Cynthia Porter

Head of Development Operations

Gabriela Burian, MD, MPH

Chief Medical Officer

Kirk Dornbush

Senior Advisor & Co-Founder

Michael Sherman

Co-Founder

Scott Geyer

Chief Technology Officer

William L. Greene, MD

CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.